{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:13:48Z","timestamp":1793103228380,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":2471,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1038\/mt.2009.220","type":"journal-article","created":{"date-parts":[[2009,9,22]],"date-time":"2009-09-22T14:06:44Z","timestamp":1253628404000},"page":"23-33","source":"Crossref","is-referenced-by-count":135,"title":["The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease"],"prefix":"10.1016","volume":"18","author":[{"given":"Richie","family":"Khanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Soska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Frascella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nastry","family":"Brignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela A","family":"Sitaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Desnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elfrida R","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J","family":"Valenzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2009.220_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/humu.10212","article-title":"Human Gene Mutation Database (HGMD): 2003 update","volume":"21","author":"Stenson","year":"2003","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2009.220_bib2","first-page":"71A","article-title":"Fabry disease: an asymptomatic hemizygote with significant residual \u03b1-galactosidase A activity","volume":"33","author":"Bishop","year":"1981","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2009.220_bib3","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/S0021-9258(18)61618-7","article-title":"Synthesis and processing of alpha-galactosidase A in human fibroblasts. Evidence for different mutations in Fabry disease","volume":"262","author":"Lemansky","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.220_bib4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2009.220_bib5","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2009.220_bib6","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1038\/mt.2009.220_bib7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00428-007-0468-6","article-title":"Cellular and tissue localization of globotriaosylceramide in Fabry disease","volume":"451","author":"Askari","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1038\/mt.2009.220_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1038\/mt.2009.220_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/08035320510028058","article-title":"Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy","volume":"94","author":"Shah","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1038\/mt.2009.220_bib10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2009.220_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF00868342","article-title":"Stroke in Fabry's disease","volume":"241","author":"Grewal","year":"1994","journal-title":"J Neurol"},{"key":"10.1038\/mt.2009.220_bib12","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200106073442303","article-title":"Evidence that human cardiac myocytes divide after myocardial infarction","volume":"344","author":"Beltrami","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2009.220_bib13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"key":"10.1038\/mt.2009.220_bib14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2009.220_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2009.220_bib16","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/hmg\/3.3.503","article-title":"Six novel mutations in the alpha-galactosidase A gene in families with Fabry disease","volume":"3","author":"Ploos van Amstel","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2009.220_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jmg.33.8.682","article-title":"Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene","volume":"33","author":"Redonnet-Vernhet","year":"1996","journal-title":"J Med Genet"},{"key":"10.1038\/mt.2009.220_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2009.220_bib19","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1038\/mt.2009.220_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1651-2227.2008.00649.x","article-title":"Early therapeutic intervention in females with Fabry disease?","volume":"97","author":"Hughes","year":"2008","journal-title":"Acta Paediatr Suppl"},{"key":"10.1038\/mt.2009.220_bib21","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/mus.10497","article-title":"Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease","volume":"28","author":"Schiffmann","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1038\/mt.2009.220_bib22","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/mt.2009.220_bib23","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/mt.2009.220_bib24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0076-6879(03)01069-3","article-title":"Cell-based screening of active-site specific chaperone for the treatment of Fabry disease","volume":"363","author":"Fan","year":"2003","journal-title":"Meth Enzymol"},{"key":"10.1038\/mt.2009.220_bib25","doi-asserted-by":"crossref","first-page":"15428","DOI":"10.1073\/pnas.192582899","article-title":"Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease","volume":"99","author":"Sawkar","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1038\/mt.2009.220_bib26","doi-asserted-by":"crossref","first-page":"13478","DOI":"10.1074\/jbc.M308523200","article-title":"Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients","volume":"279","author":"Tropak","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.220_bib27","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.220_bib28","doi-asserted-by":"crossref","first-page":"12300","DOI":"10.1073\/pnas.0404764101","article-title":"Chemical chaperones protect from effects of apoptosis-inducing mutation in carbonic anhydrase IV identified in retinitis pigmentosa 17","volume":"101","author":"Bonapace","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.220_bib29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s10545-009-1077-0","article-title":"The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines","volume":"32","author":"Benjamin","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2009.220_bib30","first-page":"A308","article-title":"Intracellular enhancement of \u03b1-galactosidase A activity in 31 Fabry lymphoblasts and fibroblasts by 1-deoxy-galactonojirimycin","volume":"65","author":"Fan","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1038\/mt.2009.220_bib31","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1038\/mt.2009.220_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0165-6147(03)00158-5","article-title":"A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity","volume":"24","author":"Fan","year":"2003","journal-title":"Trends Pharmacol Sci"},{"key":"10.1038\/mt.2009.220_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbrc.2007.05.082","article-title":"Screening for pharmacological chaperones in Fabry disease","volume":"359","author":"Shin","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mt.2009.220_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1096\/fj.04-2375com","article-title":"A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder","volume":"19","author":"Yam","year":"2005","journal-title":"FASEB J"},{"key":"10.1038\/mt.2009.220_bib35","first-page":"227","article-title":"Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype\/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes","volume":"48","author":"Ashton-Prolla","year":"2000","journal-title":"J Investig Med"},{"key":"10.1038\/mt.2009.220_bib36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/bbrc.1999.0310","article-title":"Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches","volume":"257","author":"Germain","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mt.2009.220_bib37","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF03402156","article-title":"Fabry disease: twenty novel alpha-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes","volume":"8","author":"Germain","year":"2002","journal-title":"Mol Med"},{"key":"10.1038\/mt.2009.220_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00207037","article-title":"Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease","volume":"89","author":"Ishii","year":"1992","journal-title":"Hum Genet"},{"key":"10.1038\/mt.2009.220_bib39","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.bbadis.2004.07.001","article-title":"Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease","volume":"1690","author":"Ishii","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/mt.2009.220_bib40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/jpet.108.149054","article-title":"Preclinical efficacy and safety of 1-deoxygalactonojirimycin in mice for Fabry disease","volume":"328","author":"Ishii","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1038\/mt.2009.220_bib41","doi-asserted-by":"crossref","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","article-title":"Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants","volume":"290","author":"Yam","year":"2006","journal-title":"Am J Physiol, Cell Physiol"},{"key":"10.1038\/mt.2009.220_bib42","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1172\/JCI9711","article-title":"Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation","volume":"105","author":"Abe","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1038\/mt.2009.220_bib43","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"alpha-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.220_bib44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2009.220_bib45","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy","volume":"62","author":"Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"10.1038\/mt.2009.220_bib46","doi-asserted-by":"crossref","first-page":"13813","DOI":"10.1073\/pnas.0605928103","article-title":"The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms","volume":"103","author":"Steet","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.220_bib47","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.0022-202X.2004.23303.x","article-title":"Dynamics of keratinocytes in vivo using HO labeling: a sensitive marker of epidermal proliferation state","volume":"123","author":"Hsieh","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1038\/mt.2009.220_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00418-005-0023-y","article-title":"Tubular cell proliferation in the healthy rat kidney","volume":"124","author":"Vogetseder","year":"2005","journal-title":"Histochem Cell Biol"},{"key":"10.1038\/mt.2009.220_bib49","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.chembiol.2005.09.007","article-title":"Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles","volume":"12","author":"Sawkar","year":"2005","journal-title":"Chem Biol"},{"key":"10.1038\/mt.2009.220_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF00495707","article-title":"Glycoconjugates in normal human kidney. A histochemical study using 13 biotinylated lectins","volume":"90","author":"Truong","year":"1988","journal-title":"Histochemistry"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616315775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616315775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T02:11:37Z","timestamp":1633918297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616315775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S1525001616315775"],"URL":"https:\/\/doi.org\/10.1038\/mt.2009.220","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}